PmcKwd.i
Checkpoint
Pmc
Racine
Checkpoint
Pmc
Exploration
Accueil
Racine
Racine

Serveur d'exploration Tocilizumab - Checkpoint (Pmc)

Index « PmcKwd.i » - entrée « Abatacept »
Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.
AVP-786 < Abatacept < Abatacept response  Facettes :

List of bibliographic references

Number of relevant bibliographic references: 16.
Ident.Authors (with country if any)Title
000202 (2020) Hermine I. Brunner [États-Unis] ; Nikolay Tzaribachev [Allemagne] ; Gabriel Vega Cornejo ; Rik Joos [Belgique] ; Elisabeth Gervais [France] ; Rolando Cimaz [Italie] ; Inmaculada Calvo Penadés [Espagne] ; Rubén Cuttica [Argentine] ; Thomas Lutz [Allemagne] ; Pierre Quartier [France] ; Yash Gandhi [États-Unis] ; Marleen Nys [Belgique] ; Robert Wong [États-Unis] ; Alberto Martini [Italie] ; Daniel J. Lovell [États-Unis] ; Nicolino Ruperto [Italie]Maintenance of antibody response to diphtheria/tetanus vaccine in patients aged 2–5 years with polyarticular-course juvenile idiopathic arthritis receiving subcutaneous abatacept
000429 (2020) Giovanni Cagnotto [Suède] ; Minna Willim [Suède] ; Jan- Ke Nilsson [Suède] ; Michele Compagno [Suède] ; Lennart T. H. Jacobsson [Suède] ; Saedis Saevarsdottir [Suède] ; Carl Turesson [Suède]Abatacept in rheumatoid arthritis: survival on drug, clinical outcomes, and their predictors—data from a large national quality register
000600 (2019) Gulsen Ozen [États-Unis] ; Sofia Pedro [États-Unis] ; Rebecca Schumacher [États-Unis] ; Teresa A. Simon [États-Unis] ; Kaleb Michaud [États-Unis]Safety of abatacept compared with other biologic and conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis: data from an observational study
000681 (2019) Denis Choquette [Canada] ; Louis Bessette [Canada] ; Evo Alemao [États-Unis] ; Boulos Haraoui [Canada] ; Roelien Postema [Royaume-Uni] ; Jean-Pierre Raynauld [Canada] ; Louis Coupal [Canada]Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registry
000A32 (2019) Teresa A. Simon [États-Unis] ; Maarten Boers [Pays-Bas] ; Marc Hochberg [États-Unis] ; Nicole Baker [États-Unis] ; Mary L. Skovron [États-Unis] ; Nitesh Ray ; Sanket Singhal ; Samy Suissa ; Andres Gomez-Caminero [États-Unis]Comparative risk of malignancies and infections in patients with rheumatoid arthritis initiating abatacept versus other biologics: a multi-database real-world study
000B51 (2019) Sultan M. AlmogairenAbatacept induced granulomatous hepatitis with a sarcoidosis- like reaction: a blinded trial in mice
000C20 (2018) Gonçalo Boleto [France] ; Christophe Guignabert [France] ; Sonia Pezet [France] ; Anne Cauvet [France] ; Jérémy Sadoine [France] ; Ly Tu [France] ; Carole Nicco [France] ; Camille Gobeaux [France] ; Frédéric Batteux [France] ; Yannick Allanore [France] ; Jérôme Avouac [France]T-cell costimulation blockade is effective in experimental digestive and lung tissue fibrosis
000D19 (2018) Rieke Alten [Allemagne] ; Harald Burkhardt [Allemagne] ; Eugen Feist [Allemagne] ; Klaus Krüger [Allemagne] ; Juergen Rech [Allemagne] ; Andrea Rubbert-Roth [Allemagne] ; Reinhard E. Voll [Allemagne] ; Yedid Elbez [France] ; Christiane Rauch [Allemagne]Abatacept used in combination with non-methotrexate disease-modifying antirheumatic drugs: a descriptive analysis of data from interventional trials and the real-world setting
000D48 (2017) Sarah Salomon [France] ; Caroline Guignant [France] ; Pierre Morel [France] ; Gauthier Flahaut [France] ; Clément Brault [France] ; Clément Gourguechon [France] ; Patrice Fardellone [France] ; Jean-Pierre Marolleau [France] ; Brigitte Gubler [France] ; Vincent Goëb [France]Th17 and CD24hiCD27+ regulatory B lymphocytes are biomarkers of response to biologics in rheumatoid arthritis
000D73 (2017) C. Derambure [France] ; G. Dzangue-Tchoupou [France] ; C. Berard [France] ; N. Vergne [France] ; M. Hiron [France] ; M. A. D Gostino [France] ; P. Musette [France] ; O. Vittecoq [France] ; T. Lequerré [France]Pre-silencing of genes involved in the electron transport chain (ETC) pathway is associated with responsiveness to abatacept in rheumatoid arthritis
000E56 (2016) D. S. Courvoisier [Suisse] ; D. Alpizar-Rodriguez [Suisse] ; J. E. Gottenberg [France] ; M. V. Hernandez [Espagne] ; F. Iannone [Italie] ; E. Lie [Norvège] ; M. J. Santos [Portugal] ; K. Pavelka [République tchèque] ; C. Turesson [Suède] ; X. Mariette [France] ; D. Choquette [Canada] ; M. L. Hetland [Danemark] ; A. Finckh [Suisse]Rheumatoid Arthritis Patients after Initiation of a New Biologic Agent: Trajectories of Disease Activity in a Large Multinational Cohort Study
000F12 (2016) Marie-Elise Truchetet [France] ; Nicolas Poursac [France] ; Thomas Barnetche [France] ; Emilie Shipley [France] ; Jacques-Eric Gottenberg [France] ; Bernard Bannwarth [France] ; Christophe Richez [France] ; Thierry Schaeverbeke [France]Abatacept monotherapy compared with abatacept plus disease-modifying anti-rheumatic drugs in rheumatoid arthritis patients: data from the ORA registry
000F40 (2015) Francesca De Nard ; Monica Todoerti ; Vittorio Grosso ; Sara Monti ; Silvia Breda ; Silvia Rossi ; Carlomaurizio Montecucco ; Roberto CaporaliRisk of hepatitis B virus reactivation in rheumatoid arthritis patients undergoing biologic treatment: Extending perspective from old to newer drugs
000F42 (2015) Hubert G. Nü Lein [Allemagne] ; Rieke Alten [Allemagne] ; Mauro Galeazzi [Italie] ; Hanns-Martin Lorenz [Allemagne] ; Michael T. Nurmohamed [Pays-Bas] ; William G. Bensen [Canada] ; Gerd R. Burmester [Allemagne] ; Hans-Hartmut Peter [Allemagne] ; Karel Pavelka [République tchèque] ; Melanie Chartier [France] ; Coralie Poncet [France] ; Christiane Rauch [Allemagne] ; Manuela Le Bars [France]Prognostic factors for abatacept retention in patients who received at least one prior biologic agent: an interim analysis from the observational, prospective ACTION study
001026 (2014) Hubert G. Nü Lein [Allemagne] ; Rieke Alten [Allemagne] ; Mauro Galeazzi [Italie] ; Hanns-Martin Lorenz [Allemagne] ; Dimitrios Boumpas [Grèce] ; Michael T. Nurmohamed [Pays-Bas] ; William G. Bensen [Canada] ; Gerd R. Burmester [Allemagne] ; Hans-Hartmut Peter [Allemagne] ; Franz Rainer [Autriche] ; Karel Pavelka [République tchèque] ; Melanie Chartier [France] ; Coralie Poncet [France] ; Christiane Rauch [Allemagne] ; Manuela Le Bars [France]Real-world effectiveness of abatacept for rheumatoid arthritis treatment in European and Canadian populations: a 6-month interim analysis of the 2-year, observational, prospective ACTION study
001110 (2013) Erkki J. Soini [Finlande] ; Miina Leussu [Finlande] ; Taru Hallinen [Finlande]Administration costs of intravenous biologic drugs for rheumatoid arthritis

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Sante/explor/TocilizumabV1/Data/Pmc/Checkpoint

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/PmcKwd.i -k "Abatacept" 

HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Checkpoint/PmcKwd.i  \
                -Sk "Abatacept" \
         | HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Checkpoint/biblio.hfd

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Sante
   |area=    TocilizumabV1
   |flux=    Pmc
   |étape=   Checkpoint
   |type=    indexItem
   |index=    PmcKwd.i
   |clé=    Abatacept
}}
Wicri

This area was generated with Dilib version V0.6.34.
Data generation: Fri May 22 09:34:00 2020. Site generation: Sun Mar 28 09:01:19 2021